Sunday, April 30, 2006

Biotech News - Biotech recruiter exits Alabama for Utah

Yahoo! Groups My Groups | biotech-news Main Page

Biotech recruiter exits Alabama for Utah


Biotech recruiter exits Alabama for Utah


BIRMINGHAM, Ala. Alabama's biotechnology industry recruiter, Mike Alder, is headed for Utah, where he will become Brigham Young University's technology finance director.

Alder is leaving his post as executive director of the Biotechnology Association of Alabama (BAA).


Thursday, April 27, 2006

Biotech News - Surprise Considers Biotech Pact

Surprise considers biotech pact

Surprise is considering a partnership with Sun Health Research Institute that would place a "biotech village" in the city's center and catapult it into the biotech big leagues.

John Hagen, Surprise's economic-development director, told the council that there is a shortage of laboratory and start-up space for the biotech industry. Surprise could offer that space via the biotech village, he said.

The goal would be to attract selected life-sciences ventures by developing lab start- up space. A 40-acre campus consisting of several medical-office facilities would be built in phases.

Partnering with the prestigious Sun Health Research Institute would give Surprise an advantage in attracting other biotech companies, Hagen told the council Thursday.

Wednesday, April 26, 2006

Biotech News - Cyberkinetics' Andara(TM) Combination Product Yields Nerve Regeneration

Cyberkinetics' Andara(TM) Combination Product Yields Nerve
Regeneration and Functional Recovery in Model for Chronic Spinal
Cord Injury; Andara(TM) OFS PLUS SYSTEM Data Debuted at AANS Annual

FOXBOROUGH, Mass.-- April 25, 2006--Cyberkinetics
Neurotechnology Systems, Inc. (OTCBB: CYKN; "Cyberkinetics") today
announced that the Company's research collaborators at Indiana
University and the Center for Paralysis Research at Purdue
University presented study results that demonstrate - for the first
time - that Cyberkinetics' Andara(TM) Oscillating Field Stimulator
(OFS) PLUS System, a combination product, induced nerve regeneration
and functional recovery in a preclinical model of chronic, or long-
term, spinal cord injury. These new findings build on the previously
demonstrated ability of Cyberkinetics' Andara(TM) OFS Device, used
alone, to restore sensation and some function in a Phase Ia clinical
trial of ten participants who received the device within 18 days of
their injuries.

In his presentation yesterday at the Annual Meeting of the American
Association of Neurological Surgeons in San Francisco, California,
Scott Shapiro, M.D., explained that these promising results were
achieved in a preclinical study that examined use of the Andara(TM)
OFS Device in combination with local delivery of a naturally
occurring small molecule called inosine (together, the "Andara(TM)
OFS PLUS System"). This system is the subject of a patent filing to
which Cyberkinetics holds an exclusive, worldwide license. Dr.
Shapiro is the Principal Investigator for the ongoing Phase Ib
clinical trial of the Andara(TM) OFS Device and the Robert L.
Campbell Professor of Neurosurgery at the Indiana University School
of Medicine. Richard Borgens, Ph.D., inventor of Cyberkinetics'
Andara(TM) OFS Device technology, founder of Purdue's Center for
Paralysis Research, and the Mari Hulman George Professor of Applied
Neurology in the School of Veterinary Medicine at Purdue, and Scott
Purvines, M.D., a neurosurgeon affiliated with The Brain and Spine
Center at St. Luke's Hospital in Chesterfield, Missouri, and former
intern at the Indiana University School of Medicine, were co-authors
on the study.

"The need for effective treatments for spinal cord injury is urgent
and we are currently studying the Andara(TM) OFS Device with the
goal of making a promising treatment for acute spinal cord injuries
available to surgeons as soon as possible," stated Dr. Shapiro. "The
findings reported today suggest that the Andara OFS PLUS System may
eventually make it possible to also restore function in the large
number of chronically injured patients who suffered injuries in the

"The Andara(TM) OFS Device is currently under FDA review as a
Humanitarian Device for use in patients with acute spinal cord
injuries and that indication represents a promising near-term
revenue opportunity. We believe that the exciting preclinical
results reported today provide the basis for expanding the Andara
(TM) OFS market potential by using it as a delivery vehicle, not
only for inosine, but for other neural repair factors as well," said
Timothy R. Surgenor, President and Chief Executive Officer at
Cyberkinetics. "We are also actively exploring how to move beyond
the treatment of spinal cord injuries to address the other potential
neurostimulator markets for the Andara(TM) OFS Device such as repair
of peripheral nerve injuries, strokes and traumatic brain injuries."

"The results reported today are a significant step in our efforts to
develop novel biological approaches to the medical treatment of
paralyzed people. While many emerging treatments for spinal cord
injury, such as stem cells, are still in early stages of
development, the Andara(TM) OFS platform could potentially bring
benefit to paralyzed people sooner. We believe that there is great
promise in combining OFS with a variety of neurotrophic factors, and
we look forward to further investigating this approach," said
Richard Borgens, Ph.D., inventor of the Andara(TM) OFS Device
technology platform and co-investigator for the study.

About the Study

Researchers used an animal model of chronic spinal cord injury (SCI)
to examine the usefulness of applying the Andara(TM) OFS PLUS System
versus inosine alone at 91 days post injury. The results were
referenced to a sham device control group and to historical data
from using the Andara(TM) OFS Device alone. Efficacy was evaluated
by measuring the ability to restore the cutaneous trunchi muscle
reflex (CTM) and by analyzing for regenerating axons histologically
after complete spinal cord injuries. The researchers found that the
Andara(TM) OFS PLUS System and inosine groups both exhibited
recovery of the CTM reflex at 60 days post-treatment, vs. no CTM
recovery in the control group. Notably, the CTM recovery obtained in
the Andara(TM) OFS Device PLUS group occurred in all but one subject
by one month after treatment. Furthermore, the Andara(TM) OFS Device
PLUS group showed statistically superior regeneration of ascending
and descending nerve fibers across the injury site vs. inosine
(p0.03 and p0.02, respectively) and both groups regenerated more
than the controls (p0.0001 and p0.0004, respectively).

About the Andara(TM) OFS Device and Andara(TM) OFS PLUS System

The Andara(TM) Oscillating Field Stimulator technology platform is
based upon the application of oscillating, low-voltage, direct
current of electricity to the areas above and below a spinal cord
injury. The Andara(TM) OFS Device stimulates the neural fibers
surrounding the spinal cord to grow across the injury in order to
restore sensory and motor function. Only about the size of a
lipstick tube, the device is implanted and the electrical leads are
attached onto the bone above and below the area of injury. The Andara
(TM) OFS PLUS System includes a drug pump which delivers inosine to
the area of injury. The Andara(TM) OFS Device is designed to treat
acute injuries and the Andara(TM) OFS PLUS System, which is designed
to be used with a number of neurotrophic factors, is being developed
for long-term (chronic) injuries. The proprietary therapeutic
devices are both designed to stimulate repair of central nervous
system tissue and to restore sensation and motor function.

The Andara(TM) OFS Device has already been demonstrated in Phase Ia
clinical trials to regenerate neural fibers and improve or restore
tactile sensation and movement in those with quadriplegia and
tetraplegia due to spinal cord injury when the device is implanted
within 18 days following injury. Cyberkinetics is seeking to obtain
Humanitarian Use Device (HUD) Designation from the FDA to support
the filing of a Humanitarian Device Exemption (HDE) in mid 2006. If
approved, Cyberkinetics could begin marketing the Andara OFS Device
on a limited basis as early as 2007.

About Cyberkinetics Neurotechnology Systems, Inc.

Cyberkinetics Neurotechnology Systems, Inc., a leader in the
neurotechnology industry, is developing neural stimulation, sensing
and processing technology to improve the lives of those with severe
paralysis resulting from spinal cord injuries, neurological
disorders and other conditions of the nervous system. Cyberkinetics'
product development pipeline includes: the FDA cleared-to-market
NeuroPort(TM) System, a neural monitor designed for acute inpatient
applications and labeled for temporary (less than 30 days) recording
and monitoring of brain electrical activity; the Andara(TM)
Oscillating Field Stimulator (OFS) Device, an investigational device
designed to stimulate regeneration of the spinal cord; and the
BrainGate(TM) System, an investigational device designed to provide
communication and control of a computer, assistive devices, and,
ultimately, limb movement.

Additional Information about Cyberkinetics is available at
Cyberkinetics website at

A photo of the Andara(TM) OFS Device, a fact sheet about the Andara
(TM) OFS technology and a copy of the abstract for Dr. Shapiro's
talk, Inosine Versus Oscillating Field Stimulation Plus Inosine in
Treating Experimental Chronic Spinal Cord Injury, are available
via "Media Room" at An animation
about the Andara(TM) OFS Device is available on the homepage of
Cyberkinetics' website at

Forward-Looking Statements

This announcement contains forward-looking statements, including
statements about Cyberkinetics' product development plans and
progress. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
and can be identified by the use of forward-looking terminology such
as "may," "will," "believe," "expect," "anticipate" or other
comparable terminology. Forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially
from those projected in forward-looking statements and reported
results shall not be considered an indication of our future
performance. Factors that might cause or contribute to such
differences include our limited operating history; our lack of
profits from operations; our ability to successfully develop and
commercialize our proposed products; a lengthy approval process and
the uncertainty of FDA and other governmental regulatory
requirements; clinical trials may fail to demonstrate the safety and
effectiveness of our products; the degree and nature of our
competition; our ability to employ and retain qualified employees;
compliance with recent legislation regarding corporate governance,
including the Sarbanes-Oxley Act of 2002; as well as those risks
more fully discussed in our public filings with the Securities and
Exchange Commission, all of which are difficult to predict and some
of which are beyond our control.

Cyberkinetics Neurotechnology Systems, Inc.:
Elizabeth A. Razee, 508-549-9981, Ext. 109
MacDougall Biomedical Communications
Kari Watson, 508-647-0209
Media Relations
The Investor Relations Group:
Jordan Silverstein, 212-825-3210
Investor Relations

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Monday, April 24, 2006

Biotech News - Farmers Recognize Environmental Benefits of GM Crops

Farmers Recognize Environmental Benefits of GM Crops

Hardwick sees advantages for land, wildlife and society.

St. Louis, MO April 24, 2006 -- Since first commercialized in 1996,
GM crops have enabled farmers to incorporate farming practices that
are more environmentally responsible – most notably decreased
plowing and reduced pesticide applications.

"Over the last 10 years, many farmers in our area – and I think this
is throughout the United States – have come to realize that we have
had an impact upon the environment," says U.S. farmer Jay Hardwick,
who grows biotech corn, cotton and soybeans. "With the potential of
biotechnology and reducing pesticide amounts on the landscape and
into the water systems … we're addressing those problems that are
critical to the society at large of clean air and clean water. And,
I like knowing that. And, I want to be a part of that."

According to a study released by the National Center of Food and
Agricultural Policy (NCFAP), GM crops have enabled U.S. farmers to
make annual reductions in pesticide applications of 46 million
pounds since 1996. Biotechnology has also helped farmers control
weeds without plowing the land. Leaving the farmland undisturbed has
reduced soil erosion, runoff, tractor fuel use, and greenhouse gas
emissions that result from cultivating the soil.

"We're using a lot of new biotech materials that allow us to not
cultivate the land as hard," says Hardwick in a new video and
podcast available at "As a result of us crop mixing
and keeping crop residue on the ground and alternate crops, we have
a new foraging opportunity for wildlife."

"It's just a real treat to see that," continues Hardwick. "And to
say that agriculture is helping is a real success story that needs
to be told."

Jay Hardwick's exclusive interview – as well as interviews with
three of his fellow U.S. farmers, Al Skogen, Gordon Wassenaar and
Paul Aasness – can be found at Monsanto Company's Conversations
about Plant Biotechnology website:


Michael Doane
michael.k.doane @

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - Frost & Sullivan Lauds AlgoNomics' Technology Innovation

Frost & Sullivan Lauds AlgoNomics' Technology Innovation

Frost & Sullivan presents the 2006 Technology Innovation Award in
the field of structural bioinformatics for drug discovery to Belgium-
based AlgoNomics NV for its pioneering Epibase(R) technology
platform. Offering an innovative and efficient method of identifying
T-cell epitopes, this platform has the potential to challenge
current sequence-based methodologies.

"A platform for T-cell epitope identification, Epibase(R) analyses
whether therapeutic protein leads show an increased risk for
immunogenicity and helps researchers optimise protein leads," say
Frost & Sullivan Research Analysts Ravi Shankar and Srimathy
Raghuraman. "In other words, AlgoNomics' technology helps
researchers avoid lengthy, expensive and overlapping peptide

An in silico platform, Epibase(R) assists the drug development
process at different stages. Researchers use this technology to
compare the immunogenecity of drug leads where they compare the T-
cell epitope content of large numbers of protein variants entering
the drug development stage. By identifying the T-cell epitopes at
the research level, certain drug leads can be rejected during the
early stages of drug development. This facilitates the selection of
the most promising protein leads and also helps in the removal of
the epitopes while optimising the proteins.

In cases where HLA alleles are linked with diseases, Epibase(R)
enables the exploration of drug candidates to check if they are safe
for the targeted patient population. It identifies new T-cell
epitopes based on structural bioinformatics and covers a broad range
of HLA subtypes, such as the CTL and humoral responses. Further, it
is also able to produce a high throughput on computer clusters.
Moreover, Epibase(R) does not rely on public databases as did
earlier tools such as Bimas, Tepitope, Epimatrix or Propred.

"Vis-à-vis peptide synthesis and HLA presentation experiments,
Epibase(R) performs much faster screening and provides more cost-
effective information delivery," note Mr. Shankar and Ms.
Raghuraman. "More importantly, Epibase(R) helps researchers avoid
lengthy, expensive overlapping peptide studies, which translates
into cost reductions of over 100.000 euro per protein analysed, and
a gain in speed of two weeks when compared to the typical three to
six months needed for traditional tests.

AlgoNomics' focus on structural bioinformatics R&D - which yielded
this groundbreaking technology platform - will continue, with the
company working on HLA subtypes with impact in countries such as
China, India, Indonesia, and Japan, as well as the Hispanic and
Black-American population groups.

AlgoNomics collaborates with a wide range of companies such as
Cambridge Antibody Technologies, Genmab, GSK, Evogenix, J&J Tibotec,
Innogenetics, Ablynx, Bayer Cropscience, and Evolutec.

The Frost & Sullivan Award for Technology Innovation is presented
each year to the company (or individual) that has carried out new
research, which has resulted in innovation(s) that have or are
expected to bring significant contributions to the industry in terms
of adoption, change and competitive posture.

Frost & Sullivan Best Practices Awards recognise companies in a
variety of regional and global markets for demonstrating outstanding
achievement and superior performance in areas such as leadership,
technological innovation, customer service, and strategic product
development. Industry analysts compare market participants and
measure performance through in-depth interviews, analysis, and
extensive secondary research in order to identify best practices in
the industry.

About AlgoNomics

AlgoNomics is a Belgium based biotech company that provides
structural bioinformatics services to develop rationally designed
therapeutics in the broad field of immunotherapy. AlgoNomics offers
in silico support to companies that develop rationally designed
vaccines and therapeutic proteins.

AlgoNomics owns a rich, proprietary platform for structure-based
protein and peptide design. The technology platform contains
biologically validated, innovative tools, which have been developed
in-house. AlgoNomics' premier product is the Epibase(R) platform for
T-cell epitope identification in different population groups.

For more information about AlgoNomics and Epibase(R) visit or contact

AlgoNomics N.V.
ir. Philippe Stas
Chief Operating Officer
Technologiepark 4
B-9052 Gent - Belgium
Tel.: +32-(0)9-241-11-00
Fax.: +32-(0)9-241-11-02

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been
partnering with clients to support the development of innovative
strategies for more than 40 years. The company's industry expertise
integrates growth consulting, growth partnership services and
corporate management training to identify and develop opportunities.
Frost & Sullivan serves an extensive clientele that includes Global
1000 companies, emerging companies, and the investment community, by
providing comprehensive industry coverage that reflects a unique
global perspective and combines ongoing analysis of markets,
technologies, econometrics, and demographics. For more information,
visit or contact

Frost & Sullivan
Kristina Menzefricke
Promotions Manager, Best Practices - EMEA

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - Ortec Announces Formation of Stem Cell and Regenerative Medicine Scientific Advi

Ortec Announces Formation of Stem Cell and Regenerative Medicine
Scientific Advisory Board

Appoints Noted Stem Cell Expert Daniel Marshak, Ph.D. as

NEW YORK, April 24 -- Ortec
International, Inc.
(OTC Bulletin Board: ORTN), a company focused on development and
commercialization of products applicable to regenerative medicine
and stem
cell therapy, today announced the formation of its Stem Cell and
Regenerative Medicine Scientific Advisory Board, focused on
advancing the
clinical development of the Company's newly acquired proprietary
derived advanced biomaterial technologies: Fibrin Micro Beads
(FMB's) and
Fibrin based peptides, (Haptides(TM)). FMB's have demonstrated the
to efficiently recover adult stem cells from mixed cell populations
as well
as allow for their growth, proliferation and potential
reimplantation into
the patient, and Haptides(TM) have demonstrated the ability to
enhance cell
attraction and attachment allowing for the potential development of
products for tissue regeneration and cosmetic tissue augmentation.
R. Marshak, Ph.D., highly accomplished in the field of stem cell
and human cell research, has been appointed as the Board's Chairman.
the coming months, Ortec expects to expand the Board.
Commenting on the appointment, Ron Lipstein, Vice Chairman and
CEO of
Ortec, stated, "We are quite fortunate that Dr. Marshak has agreed
to chair
our stem cell and regenerative medicine Scientific Advisory Board.
We look
forward to Dr. Marshak's guidance in charting the development and
commercialization pathway for our newly acquired advanced
biomaterials and
in generating products that can make a significant contribution to
cell therapy and regenerative medicine."
Dr. Marshak added, "I am excited to help build Ortec
Stem Cell and Regenerative Medicine Advisory Board, which will play a
guiding and directing role in the clinical development of novel
in biomaterials and stem cells."
From 1994 through 2000, Dr. Marshak was Senior Vice President
and Chief
Scientific Officer for Osiris Therapeutics, Inc., a U.S.
company developing adult stem cell products for the regeneration of
diseased or damaged tissues. From 1986-1995, he was Senior Staff
Investigator at the Cold Spring Harbor Laboratory in Long Island,
New York,
where he and the members of his laboratory conducted research in
transduction, cellular growth control and differentiation.
Concurrent with
that appointment, he was Assistant Professor, School of Medicine,
University of New York at Stony Brook, where he taught graduate
Dr. Marshak currently serves as Vice President and Chief
Officer, Biotechnology, for Cambrex Corporation (NYSE: CBM), where he
coordinates technology licensing and corporate collaborations in the
biosciences, and participates in strategic planning for the
Dr. Marshak joined Cambrex in 2000, and through 2001, led R&D
worldwide for
the Bioscience sector. Cambrex provides products and services in Life
Sciences, with 13 operating sites in the U.S. and Europe and offices
worldwide. Cambrex is a leader in providing human cells, cell
culture media
and reagents, ararose, endotoxin tests and bioassays, contract
and other custom services to the pharmaceutical industry and the
research markets. Concurrent with his position at Cambrex, Dr.
Marshak also
holds an appointment as Adjunct Associate Professor at the Johns
University School of Medicine in Baltimore, Maryland.
Dr. Marshak has extensive research experience in the growth
control of
human cells. He has authored more than 100 scientific publications,
including one textbook, and he has been editor of five monographs.
The most
recent monograph, Stem Cell Biology, was published in 2001 by The
Spring Harbor Laboratory Press. Dr. Marshak is a graduate of Harvard
University where he earned a B.A. in Biochemistry & Molecular
Biology. He
earned his Ph.D. from The Rockefeller University in Biochemistry and
Biology and conducted postdoctoral research in Pharmacology at
University School of Medicine and at the National Institutes of
Health. Dr.
Marshak has received several awards for scientific and academic
achievements, and is an inventor on five issued U.S. patents.
About Ortec International, Inc.
Ortec International, Inc. (ORTN) is a company focused on
regenerative medicine and stem cell therapy through the development
commercialization of innovative products by combining advanced cell
technology and advanced biomaterials. Ortec's lead product is OrCel
(Bilayered Cellular Matrix). Ortec's current focus is the
application of
OrCel(R) to heal chronic and acute wounds. OrCel(R) is composed of a
collagen sponge seeded with allogeneic epidermal and dermal cells.
cells secrete growth factors and cytokines normally found in acute
wounds and are believed to have a beneficial role in promoting tissue
A pivotal clinical trial evaluating a cryopreserved version of
in the treatment of venous leg ulcers has been completed and a Pre
Approval (PMA) application has been filed. Ortec is currently near
completion of patient enrollment in a confirmatory trial as a
supplement to its PMA filing. Ortec has already obtained FDA
approvals for
use of a non-frozen version of OrCel(R) in the treatment of
Bullosa and donor sites in burn patients. In addition, the FDA has
Ortec approval to initiate a pivotal (Phase III) trial evaluating
for the treatment of diabetic foot ulcers.
Through its recent merger with Hapto Biotech, Ortec acquired two
derived advanced biomaterial technologies, Fibrin Micro Beads
(FMB's) and
Haptides(TM). FBM's have the potential to play a significant role in
advancing stem cell therapy having demonstrated the ability to
recover adult stem cells and allow for their growth, proliferation,
potential reimplantation into the patient. Haptides(TM) utilize
synthetic peptides that mimic the mechanism of cell attachment to
These peptides have demonstrated the ability to significantly
enhance cell
attraction and attachment providing the potential to use Haptides
(TM) in
the development of product opportunities applicable to the cosmetic
augmentation, wound healing, orthopedics, and drug delivery markets.
For more information, visit Ortec's website at .
This news release may contain "forward-looking statements" for
purposes of the United States Securities and Exchange
Commission's "safe
harbor" provisions under the Private Securities Litigation Reform
Act of
1995 and Rule 3B-6 under The Exchange Act. Without limitation,
regarding expected FDA approvals, clinical trial results, product
performance, expectations with respect to sales, gross margins,
and development expenditures, earnings per share, capital
collaborations, or other expansion opportunities would be "forward-
statements." These statements may be identified by words such
as "expects",
"anticipates", "intends", "estimates", "believes" or similar
expressions in
connection with any discussion of future financial and operating
performance. The forward- looking statements contained herein
involve risks
and uncertainties that may cause results to differ materially from
Company's expectations including but not limited to, global economic
trends, competitive pricing or product developments, government
and/or regulations, technology, manufacturing, legal and patent
suppliers, capital availability, personnel changes, cancellation or
in renewal of contracts, and lack of suitable raw materials or
materials. Investors are cautioned to review risk factors in the
filings with the United States Securities and Exchange Commission.

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotechnology: Still Fueling Controversy

Biotechnology: Still Fueling Controversy

By Charles Shaw, AlterNet. Posted April 21, 2006.

As America responds to its oil addiction, the biotech industry is once again promising to save the world. And this time, they just might mean it. Tools

It should have been one of the more earth-shattering admissions of the last hundred years when George W. Bush -- the former Texas oilman who steadfastly denies that oil ever played a part in our decision to invade Iraq -- announced that America was in fact "addicted to oil."

Instead, America's response was more akin to hearing one's 55-year-old effeminate bachelor uncle come out of the closet to the family at a holiday dinner: Everyone knew it already, but no one ever expected him to say it.

However, the evidence is indeed staggering. The United States of America uses more than a quarter of the world's annual oil production; the current administration is comprised of oil executives; our foreign policy apparatus consists of a reckless form of petro-diplomacy that requires us to prop up brutal regimes or overthrow unfriendly governments.

The situation has made our economic well-being so dependent on oil that even the slightest interruption to the oil supply has far-reaching ramifications, as we saw first with the removal of Iraqi oil from the world market, and then the refinery catastrophe in the wake of hurricanes Katrina and Rita.

BioWorld Top 25 Biotechnology Drugs Report

BioWorld Top 25 Biotechnology Drugs Report


"The multi-billion dollar biotechnology drug market has emerged from the shadow of the pharmaceutical industry and merits critical analysis of its leading products. This new report from BioWorld Today profiles and examines the drugs driving this market and attracting
investor attention."

The BioWorld Top 25 Biotechnology Drugs Report is the first report of its kind: It delivers a comprehensive and in-depth analysis of the top 25 biotech drugs, as ranked by revenue, in one single report, and provides you with the knowledge you need to take quick action on vital business decisions related to the biotech drug market.

An attempt to research this information can lead you in many different directions, but with the BioWorld Top 25 Biotechnology Drugs Report, you can access extensive profiles of each of the top 25 leading products. Analysis includes:

Disease description & statistics
Chronology of development through approval
Patent protection dates
Competing drugs on the market and in development
Secondary indications in development
Partnerships involved in the drug
Projection of the drug's short-term future

Africa cannot ignore food biotechnology

Africa cannot ignore food biotechnology


ACHIEVING adequate food with nutritional requirements for all people is one of the prime challenges facing most developing countries, particularly in the sub-Saharan region.

In Africa, for example, governments have made it almost like an annual habit to ask for food aid claiming that crops had failed due to unfavourable weather conditions and inadequate rainfall.

This is the excuse that countries, including Kenya, where agriculture is the lifeline of over 80 percent of rural folks and also provides 70 percent employment, continue to give.

Research shows that farming constraints such as inappropriate technologies for small holder farmers, high cost of farm inputs, farm fragmentations, etc that Kenya continue to give as an excuse to justify itsr begging spree are a thing of the past.

According to Prof. Onesmus ole Moi Yoi of the Institute of Molecular and Cell Biology Africa, such constraints have been eliminated in other parts of the world through use of science and technology.

Biotechnology News - Biotechnology Advocates Look to a Brighter Future through Genetic Engineering

Biotechnology News - Biotechnology Advocates Look to a Brighter Future through Genetic Engineering

By Robert Wildeboer
24 April 2006

Biotechnology can eradicate disease, provide renewable energy, solve the problem of world hunger and help the local economy. That was the message at this month's Biotechnology Industry Organization conference in Chicago.

Convention atttendees wait in line to get a Guinness Beer at the Ireland exhibit at the Biotechnology Industry Organizations 2006 convention
In this crowd of 20-thousand conference attendees, there doesn't seem to be a single pessimist. Almost everyone here thinks biotechnology - a fledgling industry that manipulates living cells to create useful products - has the potential to solve the world's most pressing problems, from disease and hunger to poverty and pollution.

Lois Fergusson is standing in an exhibit that looks like an upscale American kitchen. She points to the products used to make this 'green' kitchen. "Our countertop is made from hemp and then here we have our cupboards, [they] are made from wheat straw, very strong and it's a renewable resource." She says this type of manufacturing will allow Americans to maintain their high standard of living without putting so much pressure on the environment.

Sanofi-Aventis Purchases Additional Land in Oro Valley to Support Future Expansion of its Research & Development Facility

Sanofi-Aventis Purchases Additional Land in Oro Valley to Support Future Expansion of its Research & Development Facility

BRIDGEWATER, N.J., April 10, 2006 -- Sanofi-aventis, the world's third largest pharmaceutical company, announced today that it has purchased approximately 11.54 acres of land in Innovation Park, Oro Valley, Arizona. The company will move its research and development center from the current location in Oro Valley on Hanley Boulevard into a larger location to support future growth. Financial details of the agreement were not disclosed.

While the design of the new building is currently in development, the building's size will be approximately 100,000 square feet. This is more than double the space at the current facility. The new site is located at the corner of Rancho Vistoso Boulevard and Innovation Park Drive. Innovation Park, a 300-acre high tech campus, is becoming a significant biotech hub for northern Tucson. Construction is expected to begin on the new facility in the first quarter of 2007.

"The new site was chosen because it can accommodate our growing needs for a more flexible and integrated space," says Porter McMillian, Senior Vice President, U.S. Science & Medical Affairs for sanofi-aventis. "In addition, we are pleased to stay in Oro Valley and be a part of the biotech growth. The beautiful mountain landscape also made the site location a perfect choice."

Steve Corney, Managing Principal of The Staubach Company, sanofi-aventis' site selection firm for this project said "The combination of the existing biotech cluster at Innovation Park and the lifestyle and amenities of Oro Valley, made this an excellent location for sanofi-aventis."

The 65 sanofi-aventis employees currently working at the combinatorial technologies center on Hanley Blvd. have expertise in biology, chemistry, information systems and automated organic synthesis. They are expected to move into the new facility by the end of 2008. Sanofi-aventis is planning to recruit twenty more talented scientists over the next three to five years.

About sanofi-aventis

Sanofi-aventis is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris and in New York .

Wednesday, April 19, 2006

Biotech News - Science Foundation Arizona Names William C. Harris President/CEO

Science Foundation Arizona Names William C. Harris President/CEO;
Director of Science Foundation Ireland will take helm of Science
Foundation Arizona this summer

PHOENIX, Arizona--Mar 24, 2006 - Science Foundation Arizona (SFA)
has named William C. Harris, Ph.D., president and chief executive
officer of the Arizona-based nonprofit organization. He will assume
his new role this summer.

As leader of SFA, Harris will be responsible for fostering a culture
that will build and strengthen medical, scientific and engineering
research programs and infrastructure in areas of greatest strategic
value to Arizona's competitiveness in the global economy. He will
also work to actively engage scientific research, academic and
medical institutions representing both the public and private
sectors on a worldwide basis.

Harris comes to SFA with remarkable credentials, having served as
founding director general of Science Foundation Ireland (SFI) for
almost 5 years. Harris was largely responsible for SFI's success as
a global bio/ICT research model. Information and communication
technology (ICT) includes computer science, engineering and
mathematics, which are key to modern bio, particularly systems
biology and personalized medicine.

Harris' work of turning Ireland into an internationally
collaborative partner with multiple biotech, academic-industry
research groups and his establishment of a comprehensive grants
program with an international review system was integral in
Ireland's success for building research investments in strategic
areas and developing a knowledge driven economy.

"Arizona will benefit immediately from Dr. Harris' nearly 3 decades
of experience in managing funds towards the advancement of science
and engineering. His success in Ireland was based on the
establishment of a globally competitive, comprehensive grants
program, focused principally for bioscience/bioengineering and ICT,"
said Dr. Jeffrey Trent, president and scientific director of the
Translational Genomics Research Institute (TGen). "There is no doubt
in my mind that under Bill's direction, Science Foundation Arizona
(SFA) will keep this same commitment to excellence and will be of
resounding benefit to all Arizonans."

"Harris' appointment brings incredible opportunity to the state of
Arizona. He will be critical in attracting top-quality researchers,
doctors and collaborative partnerships to the state," said Don
Budinger, chairman and founding director of the Rodel Foundations of
Arizona and founding chair of SFA. "He brings great insight into the
importance of innovation coupled with the experience of how to
establish a globally competitive, comprehensive R&D model with the
goal of growing a more competitive knowledge driven economy for

Harris' appointment marks a milestone in the infancy of SFA's
development. He will report to a yet-to-be named board of directors.

"Science Foundation Arizona hopes to improve access to quality
medical care for all Arizonans," said John Murphy, president and CEO
of the Flinn Foundation and founding director of SFA. "At the same
time, it hopes to build an economy that will create higher paying
jobs, improve our state's educational system and foster recognition
of our state in the global community as a place for innovation and
excellence. On a trip to Ireland last summer I saw first-hand the
results of Harris' work. He brings instant credibility to our
aspirations for Arizona."

Prior to joining SFA, Harris served as director general and CEO of
Science Foundation Ireland where he was able to establish strong
relationships and international collaborations while instituting
globally competitive grants programs and securing a solid funding
base. Harris also served as the director of the Mathematical and
Physical Sciences at the U.S. National Science Foundation, founding
president and executive director of Columbia University's Biosphere
2 Centre (B2C) and as vice-president for research and professor of
chemistry and biochemistry at the University of South Carolina, and
also led the USC Research Foundation.

Harris has authored more than 50 research papers and is a fellow of
the American Association for the advancement of Science. In 2004, he
received the Wiley Lifetime Achievement Award from California
Polytechnic State University and was recently elected a member of
the Royal Irish Academy. Harris earned his Bachelor of Science
degree at the College of William and Mary and his Ph.D. in chemistry
at the University of South Carolina.

"Arizona has the capacity to position itself as a hub of bioscience,
industry and scientific advancements that lead to improved
healthcare and quality of life throughout the state," said
Harris. "I look forward to joining Science Foundation Arizona (SFA)
and Arizona's already well established bioscience partners, in
distinguishing the state as a nationwide collaborator and
international leader in the biosciences and related disciplines
essential for a 21st century competitive economy."

Science Foundation Arizona (SFA) is a 501(c)(3) nonprofit
organization created by the Greater Phoenix Leadership, Inc. (GPL),
Southern Arizona Leadership Council (SALC)and the Flagstaff 40 as a
result of Arizona's Bioscience Roadmap, developed by the Battelle
Memorial Institute with funding from the Flinn Foundation. SFA has
goals to (1) build and strengthen medical, scientific and
engineering research programs and infrastructure in areas of
greatest strategic value to Arizona's competitiveness in the global
economy, and (2) actively engage scientific research, academic and
medical institutions representing both the public and private
sectors on a worldwide basis. SFA will be active in helping Arizona
to position itself as a hub of bioscience, industry and scientific
advancements that lead to improved healthcare and quality of life
throughout the state.

Contact Denise Resnik & Associates Denise D. Resnik, 602-956-8834

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Biotech News - Amazon Biotech, Inc. Announces Submitting of a Protocol to Test AMZ0026

Amazon Biotech, Inc. Announces Submitting of a Protocol to Test
AMZ0026 as an HIV Drug to Delay Onset of AIDS With the FDA

NEW YORK, April 18, 2006 -- Amazon Biotech, Inc. (OTCBB:AMZB) today
announced that it has filed a protocol to test AMZ0026 as an HIV
drug to delay onset of full-blown AIDS with the Food and Drug
Administration (FDA). The study is designed to include 60 non-
symptomatic HIV-infected subjects who have not been recently treated
with any AIDS medications. AMZ0026 versus placebo will be
administered for a 6 month treatment period, during which primary
endpoint parameters will be monitored, including "T" Cell increases
and the amount of HIV virus in the bloodstream. The drug formulation
is based upon the Amazon Biotech, Inc. philosophy of several active
ingredients working in combination, utilizing cutting edge whole
plant pharmaceutical drug technology to create a natural, healthier
pharmaceutical drug.

The new AMZ0026 HIV protocol is designed to evaluate this
investigational drug's ability to prevent the progression to AIDS in
HIV-infected individuals through assessment of AMZ0026's effect on
benchmark clinical markers for AIDS in this six month study.
Submission of a protocol with the FDA does not guarantee that the
FDA will approve the protocol, nor does it mean that there won't be
changes made in the protocol. Amazon Biotech is working closely with
the FDA, hoping to arrive at a protocol that will satisfy first and
foremost, all safety concerns and also show efficacy. Commitment to
do a study does not represent that the Company has FDA approval on
the Protocol to start the study.

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company,
primarily developing immune modulator drugs. AMZ 0026 is the
Company's first such drug, to be used for the treatment of HIV/AIDS.
The Company plans on initiating Phase I/II clinical studies of AMZ
0026 in the near future, with an eventual goal of attracting a joint
venture partner with a major pharmaceutical company in Phase III
trials, or follow the FDA Fast Track program to market. Amazon
Biotech specializes in natural plant pharmaceutical drugs and is
focused on bringing healthier pharmaceutical drugs to market.

Additional information on Amazon Biotech may be found at:

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation
Reform Act of 1995 This press release contains forward-looking
information within the meaning of Section 21E of the Securities
Exchange Act of 1934, including statements regarding any potential
sales of products as well as statements that include the
words "believes," "expects," "anticipates," or similar expressions.
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of Amazon Biotech, to differ materially
from those implied or expressed by such forward-looking statements.
Such factors include, among others, the risk factors included in
Amazon Biotech's subsequent reports filed with the Securities and
Exchange Commission under the Exchange Act. This press release
speaks as of the date first set forth above and Amazon Biotech
assumes no responsibility to update the information included herein
for events occurring after the date hereof.

Rick Lutz
(404) 261-1196

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Monday, April 17, 2006

Biotech News - TGen and ASU Technopolis present the 2nd Annual Commercializing Arizona Life Sci

TGen and ASU Technopolis present the 2nd Annual Commercializing
Arizona Life Sciences Forum: Financing and Investing for Life Sciences
Researchers, Entrepreneurs and Inventors at the Phoenix Airport

April 20-21

There will be keynote speaker presentations and panelists discussing
the ABCs of investing in life sciences companies, the status of the
Arizona life sciences industry and company development, Arizona tax
incentives for life sciences investors, strategic partnerships and
collaborations, IP protection and more.

For more information, contact Karen Katzorke at 480-727-7905 or
(, or register online at

Yahoo! Groups Links

<*> To visit your group on the web, go to:

<*> To unsubscribe from this group, send an email to:

<*> Your use of Yahoo! Groups is subject to:

Thursday, April 13, 2006

Biotech News - ASU Technopolis and TGen Team up for Second Life Sciences Forum

Yahoo! Groups My Groups | biotech-news Main Page

ASU Technopolis and TGen Team up for Second Life Sciences Forum

Focus on Financing and Investing for Life Science Researchers, Entrepreneurs and Investors


ASU Technopolis and the Translational Genomics Research Institute (TGen) have once again joined forces to present the 2nd Annual Commercializing Arizona Life Sciences Forum on April 20 & 21 at the Phoenix Airport Marriott.

The Forum sessions are divided into two tracks, allowing investors/venture capitalists and researchers/entrepreneurs to receive information tailored to their respective needs. Confirmed keynote speakers include Dr. Fred Craves, co-founder and managing director, Bay City Capital; Dr. Kerry Dance, managing director, Hamilton Bioventures; Dr. Mark Ferguson, founder and CEO, Renovo of the United Kingdom; and Jack J. Florio, vice president, communications/board member of the San Diego Tech Coast Angels.

Registration is available online at

Session highlights for investors and venture capitalists, featuring keynote speaker presentations and panelists, include:

  • The ABC's of Investing in Life Science Companies
  • The Status of the Arizona Life Science Industry and Company Development
  • Life Science Case Study
  • Arizona Tax Incentives for Life Science Investors
  • Hosted tours of the Biodesign Institute at ASU and the Translational Genomics Research Institute (for investors/venture capitalists only)
  • Investor-only luncheon hosted by TGen

    Session highlights for researchers and entrepreneurs, featuring keynote speaker presentations and panelists, include:

  • Strategic Partnerships and Collaborations
  • Commercializing Life Sciences with the Government
  • IP Protection
  • Commercialization and Licensing
  • Entrepreneurial Start-up
  • Arizona Tax Incentives for Life Science Investors
  • SBIR Phase I and Phase II Proposal-Writing Workshop (with a Certificate of Completion)

    "The Annual Commercializing Arizona Life Sciences Forum is yet another opportunity for Arizona to advance innovations in the biosciences – a critical sector that continues to garner much attention and interest from our state legislators and business leaders," remarked ASU President Michael Crow.

    "This Forum provides a great opportunity to forge the critical connections between researchers, entrepreneurs, venture capitalists and investors that will catalyze commercialization," said Ellen Feigal, M.D., TGen deputy director of Clinical Sciences and director, Division of Molecular Imaging.

    ASU Technopolis is the high impact and focused initiative of Arizona State University's President Michael Crow to move research in technology and the life sciences into the private sector and propel Greater Phoenix into the international economic arena as a viable player. A combination of targeted entrepreneurial education, coaching, and networking is producing results that will fuel business expansion, job growth, and greater prosperity for the people of Arizona. Through ASU Technopolis, entrepreneurs are connected to potential investors, board members, service providers, partners, customers, research and development collaborators, and other ASU units and programs.

    ASU's Office of Economic Affairs (within the Office of the Vice President for Research and Economic Affairs) administers the ASU Technopolis program. Visit for more information.

    The Translational Genomics Research Institute (TGen) is focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. TGen is focused on personalized medicine and plans to accomplish its goals through robust and disease-focused research. Visit TGen at for more information.



    Karen Leland,


    Office of Economic Affairs

    Arizona State University

    Amy K. Erickson, 602-343-8522






    Monday, April 03, 2006

    Biotech News - BioInvent and Immusol Collaborate on Antibody Therapeutic Macular Degeneration

    BioInvent and Immusol to Collaborate on Antibody Therapeutic for
    Macular Degeneration

    April 3, 2006--BioInvent International AB (SAX:BINV) and Immusol,
    Inc. announced today a collaboration for the development of a fully
    human n-CoDeR(R) antibody for the treatment of age-related macular
    degeneration (AMD) and other ophthalmic disorders. Macular
    degeneration, a poorly treated condition, is the most common cause
    of vision loss in people over 60, affecting 20-25 million people
    worldwide. It is characterised by abnormal and uncontrolled vessel
    growth in the eye.

    The collaboration will bring together a rich portfolio of expertise
    in the area of therapeutic antibody research and development.
    Immusol will contribute its expertise in ophthalmology and
    intellectual property rights covering the use of antagonists against
    a biological target identified to play an important role in the
    underlying pathological process of AMD. BioInvent will contribute
    its knowledge and experience in angiogenesis, immunology and
    therapeutic antibody discovery and development. Under the terms of
    the collaboration, the parties will share costs and revenues in
    further development and commercialization.

    Commenting on the collaboration, Svein Mathisen, President and CEO
    of BioInvent, said, "We are very pleased to add this project to our
    growing portfolio and to work with Immusol's expertise in ophthalmic
    disorders. We believe that this project if successfully developed
    could potentially offer significant clinical benefit to a patient
    population poorly treated today."

    Dr. Flossie Wong-Staal, Chief Scientific Officer and Executive Vice
    President of Research and Development of Immusol, said, "We are
    happy to work with BioInvent to leverage BioInvent's antibody
    expertise in an important disease area. By developing antibodies
    against a non-VEGF target with proven preclinical efficacy, we hope
    to tackle wet AMD from a different angle."

    Legal disclaimer

    This press release contains statements about the future, consisting
    of subjective assumptions and forecasts for future scenarios.
    Predictions for the future only apply as of the date they are made
    and are, by their very nature, in the same way as research and
    development work in the biotech segment, associated with risk and
    uncertainty. With this in mind, the actual outcome may deviate
    significantly from the scenarios described in this press release.

    Notes to editors:

    BioInvent International AB, listed on the O list of the Stockholm
    Stock Exchange (SAX:BINV), develops therapeutic antibodies against
    diseases where there is a significant unmet medical need. Antibodies
    are a strongly growing segment of the pharmaceutical market.

    BioInvent focuses on discovery and development of therapeutic
    antibodies, and documents their effect in pre-clinical and early
    clinical trials. Clinical development, marketing and distribution
    are conducted in cooperation with established pharmaceutical
    companies. Today BioInvent conducts innovative drug projects
    involving conditions such as HIV infection, thrombosis, cancer and

    These projects are based on a competitive technology platform that
    covers the entire chain from the n-CoDeR(R) antibody library for
    fast and efficient selection of human antibodies, to production in a
    facility fully approved for manufacturing biological drugs. The
    scope and strength of this platform is also utilised by partners in
    the development of new drugs. These partners include ALK-Abello,
    Antisoma, UCB, GlaxoSmithKline, Igeneon, ImmunoGen, OrbusNeich,
    Syngenta and XOMA.

    The Company, which currently has 96 employees, is located at Ideon
    in Lund.

    Immusol, Inc. is a privately-held San Diego-based biopharmaceutical
    company engaged in the discovery and development of novel therapies
    to treat human diseases. Immusol uses an integrated approach,
    starting with a proprietary discovery technology, to identify
    therapeutic molecules involved in the areas of cancer, viral
    infection, and ophthalmology. Based on these discoveries, Immusol
    develops small molecule and protein-based therapies alone or in
    collaboration with drug development partners. Immusol's lead drug
    candidate, ChelASE, is being studied in phase II clinical trials for
    the treatment of keloids and hypertrophic scars. Other drug
    candidates are in various stages of pre-clinical and clinical

    Yahoo! Groups Links

    <*> To visit your group on the web, go to:

    <*> To unsubscribe from this group, send an email to:

    <*> Your use of Yahoo! Groups is subject to:

    Biotech News - inChord Communications Agencies and CEO to be Recognized at 17th Annual Med Ad N

    Yahoo! Groups My Groups | biotech-news Main Page

    inChord Communications Agencies and CEO to be Recognized at 17th Annual Med Ad News Manny Awards
    * Blane Walter, CEO of inChord, To Be Honored as Advertising Person of the

    * GSW Worldwide, The Navicor Group and Palio Communications Receive Award

        COLUMBUS, Ohio, April 3 inChord Communications, now
    inVentiv Communications, a division of inVentiv Health (Ventiv Health, Inc.,
    Nasdaq: VTIV), and three of its advertising agencies will be honored by Med Ad
    News on April 20 at the 17th annual Manny Awards, an awards program that
    recognizes excellence among healthcare advertising agencies.
        R. Blane Walter, CEO of inChord Communications and president and CEO of
    inVentiv Communications, will be honored as "Advertising Person of the Year."
    The award is presented to a senior-level industry leader who, during the past
    year, has made extraordinary professional achievements, elevated his or her
    business to new heights, and advanced the industry through outstanding and
    innovative actions.  At age 35, Walter is the youngest person to ever receive
    the award.
        In addition to recognizing Walter, Med Ad News has also nominated three
    inChord agencies -- Palio Communications, The Navicor Group and GSW Worldwide
    -- for 2006 Manny Awards.  This year, the publication will present "Agency of
    the Year" awards in three categories, based on revenue size.  Palio
    Communications is nominated for Agency of the Year in Category II ($10 - $50
    million in revenue).  The Navicor Group is nominated for Agency of the Year in
    Category III ($2 to $10 million in revenue). Nominees for the Agency of the
    Year Awards are judged on creative track record, management strength,
    financial performance, strategic thinking, account wins and losses, and
    ability to attract talent.
        GSW Worldwide is nominated for Most Creative Agency, an honor recognizing
    the agency that has produced the most outstanding compilation of creative work
    over the past year.  In addition, GSW is nominated for Best Disease Awareness
    Advertisement for an ad it created for TAP Pharmaceuticals in the
    hyperuricemia category; and for Best Pro-Bono Advertisement for an ad it
    created for Columbus Children's Hospital.  All creative awards are determined
    by votes from creative directors at the agencies polled by Med Ad News.
        "The Manny Awards are widely recognized to be one of the highest honors
    within our industry," said Walter. "It is a tremendous distinction to be named
    Advertising Person of the Year, but I'm even more proud of the nominations
    that our agencies have received. They reinforce my conviction that we are
    leading the industry with innovative thinking, strategic vision and creative
        Manny Award winners will be announced on April 20 at the awards ceremony,
    to be held at the Sheraton New York Hotel and Towers in New York City.

        inChord Communications is a global group of specialized communication
    companies working together to provide customized marketing solutions to the
    health and wellness industry, including many of the world's top pharmaceutical
    and biotech companies. Based in Columbus, Ohio, inChord has more than 700
    employees and offices in 11 major global markets.  inChord is an inVentiv
    Health company.  For more information, please go to

        About inVentiv Health
        inVentiv Health (Ventiv Health, Inc., Nasdaq: VTIV) is the leading
    provider of commercialization and complementary services to the global
    pharmaceutical, life sciences and biotechnology industries. inVentiv delivers
    its customized clinical, sales, marketing and communications solutions through
    its three core business segments: inVentiv Clinical, inVentiv Communications,
    and inVentiv Commercial.  inVentiv Health works with over 150 pharmaceutical
    and life sciences clients, including 18 of the top 20 global pharmaceutical
    companies.  For more information, visit

        This press release contains forward-looking statements within the meaning
    of the Private Securities Litigation Reform Act of 1995.  Such forward-looking
    statements involve known and unknown risks that may cause Ventiv Health's
    performance to differ materially.  Such risks include, without limitation:
    changes in trends in the pharmaceutical industry or in pharmaceutical
    outsourcing; our ability to compete successfully with other services in the
    market; our ability to maintain large client contracts or to enter into new
    contracts; and, our ability to operate successfully in new lines of business.
    Readers of this press release are referred to documents filed from time to
    time by Ventiv Health, Inc. with the Securities and Exchange Commission for
    further discussion of these and other factors.


    Biotech News - Trinity BioGenics Acquires Lab and Intellectual Proper - Maui General Store

    Yahoo! Groups My Groups | biotech-news Main Page

    Source: Maui General Store

    Trinity BioGenics Acquires Lab and Intellectual Properties

    Maui General Stores Inc. dba Trinity BioGenics Corp. (OTCBB:MAUG), a research and development company focused on making Adult Stem Cell procedures commercially available in conjunction with Immune Therapy, is pleased to announce that it has acquired intellectual property and laboratory assets formerly owned by Patho Biotech. This acquisition is key to the Company's future development of commercial therapeutic & diagnostic products based on the identification of nano-bacteria.

    The Company's lab is operated by Dr. Luther Lindner, M.D. Dr. Lindner is a physician (pathologist) on the faculty of Texas A&M University -- College of Medicine. He is studying human blood bacterium, believed to be associated with chronic fatigue and immune dysfunction syndrome (CFIDS), fibromyalgia, and several autoimmune disorders including multiple sclerosis, lupus erythematosis, and rheumatoid arthritis.

    Trinity BioGenics will use this facility to establish a research and processing laboratory to create commercial products only available via the Company's license agreement for use nationally and abroad.

    Trinity BioGenics CEO, Lawrence Stowe, stated, "The acquisition of this laboratory marks an important moment in the history of Trinity BioGenics. With the potential of our newest facility we will be able to further develop our research capability, which is our primary objective at this moment in time."

    For all future Trinity BioGenics investor relations needs, investors are asked to visit the Trinity BioGenics IR Hub at where they can post questions and receive answers within the same day, or simply review questions and answers posted by other investors. Alternatively, investors are able to e-mail all questions and correspondence to where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

    About Trinity BioGenics Corp.

    Trinity BioGenics Corp works exclusively within the Adult Stem Cell and Biological Medicine areas. The Company's proprietary protocols are advanced, and use specific processes to obtain desired results. The FDA classifies the Company's process as a unique blood product; therefore, it will be specific and unique to Trinity BioGenics Corp. Additionally, the Company's unique combination of Immune Therapy and Adult Stem Cell treatments are like no other treatment experienced. The Company's Adult Stem Cell protocol is under preparation for Human Clinical Studies.

    The statements made in this press release, which are not historical facts, contain certain forward-looking statements concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement.

    CONTACT:  Trinity BioGenics
              Dr. Lawrence Stowe

              Investor Relations
              AGORA Investor Relations



    Biotech News - GPC Biotech Presents New Satraplatin Pre-clinical Data at AACR

    Yahoo! Groups My Groups | biotech-news Main Page

    GPC Biotech Presents New Satraplatin Pre-clinical Data at AACR
    Monday April 3, 4:12 am ET

    Therapeutic synergism in vivo when satraplatin is combined with Taxotere(R) (docetaxel) in non-small cell lung cancer model
    Strong synergistic effect when satraplatin's active metabolite, JM-118, is combined with Herceptin(R) (trastuzumab) in breast cancer cells

    WALTHAM, Mass. and PRINCETON, N.J. -- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Nasdaq: GPCB) today announced the presentation of new pre-clinical data on its lead drug candidate satraplatin at the 97th Annual Meeting of the American Association for Cancer Research (AACR) in Washington, DC.

    "The data presented at AACR are supportive of the clinical work we have underway to explore the potential of satraplatin in a variety of combination therapies and cancer settings," said Marcel Rozencweig, M.D., Senior Vice President, Drug Development. "We currently have ongoing two Phase 1 trials evaluating satraplatin in combination with Taxotere in advanced solid tumors. We also have underway a Phase 2 study evaluating satraplatin in metastatic breast cancer, and we expect to further explore satraplatin in this treatment setting in combination with other therapies, such as Herceptin."

    A poster entitled, "Synergistic antitumor activity of the combination of satraplatin and docetaxel in H460 human non-small cell lung carcinoma xenografted in nude mice," (Abstract #563) showed results from in vivo studies evaluating the efficacy of satraplatin and Taxotere® (docetaxel), both individually and in combination, using various dosing and treatment schedules. Within the range of doses and schedules tested, a combination of the two compounds administered sequentially results in therapeutically synergistic effects -- i.e., superior to the best result that could be obtained with either agent administered individually -- with no apparent increase in toxicity compared to either single agent in this tumor model. Results evaluating satraplatin and Taxol® (paclitaxel) in this non-small cell lung cancer model were presented in late 2005. The pre-clinical results presented at AACR build on previous data evaluating satraplatin in combination with Taxotere in cells and may be useful in developing appropriate dosing schedules for clinical testing of a combination therapy of satraplatin and Taxotere.

    A poster entitled, "Synergistic in vitro anticancer activity of JM118, a metabolite of satraplatin, in combination with Herceptin," (Abstract #1350) evaluated satraplatin's active metabolite, JM118, in combination with Herceptin® (trastuzumab) against SKBR-3 breast cancer cells, which are known to be sensitive to Herceptin. The data showed that, within the range of doses and schedules tested, both concurrent and sequential exposure of the cells to these two compounds resulted in strong synergistic cytotoxic activity. GPC Biotech currently has underway a Phase 2 trial evaluating satraplatin in patients with metastatic breast cancer. The Company is conducting this study to gain more insight into the activity of satraplatin in this important cancer area. The data presented support further exploration of the combination of satraplatin and Herceptin in breast cancer patients.

    About Satraplatin

    Satraplatin, an investigational drug, is a member of the platinum family of compounds. Over the past two decades, platinum-based drugs have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. Unlike the platinum drugs currently on the market, all of which require intravenous administration, satraplatin is an orally bioavailable compound and is given as capsules that patients can take at home. An oral platinum drug could offer key advantages, including ease of administration and patient convenience, in a variety of applications. GPC Biotech believes that satraplatin is also the only platinum compound that has demonstrated activity in a randomized trial in hormone-refractory prostate cancer (HRPC).

    GPC Biotech has completed patient enrollment in a Phase 3 registrational trial -- the SPARC trial -- which is assessing the safety and efficacy of satraplatin in combination with prednisone as a second-line chemotherapy in patients with HRPC. In December 2005, the Company initiated the rolling submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). Also in December 2005, GPC Biotech signed a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion was granted exclusive commercialization rights to satraplatin for Europe and certain other territories.

    Satraplatin has been studied in clinical trials involving a range of tumors, and Phase 2 trials have been completed in HRPC, ovarian cancer and small cell lung cancer. Other trials evaluated the effects of adding satraplatin to radiation therapy, a clinical application in which satraplatin's oral bioavailability could be particularly advantageous. A Phase 1/2 study evaluating this combination in patients with non-small cell lung cancer has been initiated. Several other Phase 1 and 2 studies evaluating satraplatin in combination with other therapies and in various cancers are underway or planned. GPC Biotech in-licensed satraplatin from Spectrum Pharmaceuticals, Inc. in 2002. Additional information on satraplatin can be found in the Anticancer Programs section of the Company's Web site at

    GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company's lead product candidate -- satraplatin -- has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company's Web site at

    This press release may contain forward-looking statements. Forward- looking statements may be, but are not necessarily, identified by words like "believe", "anticipate", "intend", "expect", "target", "goal", "estimate", "plan", "assume", "may", "will", "could" and similar expressions. Forward-looking statements include, but are not limited to, statements about the progress, timing and completion of research, development, pre-clinical studies and clinical trials for the Company's product candidates; the timing and ultimate success in obtaining regulatory approval in the U.S., Europe or any other jurisdiction for satraplatin or any other product candidates; the Company's ability to market, commercialize, achieve market acceptance for and sell the Company's product candidates; the Company's ability to adequately protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; and the Company's estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. There can be no guarantee that the

    pre-clinical data discussed in this press release will be useful in determining appropriate dosing and schedules for a combination of satraplatin and Taxotere, nor that satraplatin in combination with Taxotere or with Herceptin will be safe and effective in clinical studies. There can be no guarantee regarding the timing or outcome of ongoing clinical studies with satraplatin. Additionally, there can be no guarantee that satraplatin will be approved for marketing in a timely manner, if at all. Forward-looking statements in this press release are based on the Company's current expectations and projections about future events and are subject to risks, uncertainties and assumptions. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur. We direct you to the Company's Form 20-F, as amended, for the fiscal year ended December 31, 2004 and other reports filed with the U.S. Securities and Exchange Commission (SEC) for additional details on the important factors that may affect the Company's future results, performance and achievements. Except as required by law, the Company disclaims any intent or obligation to publicly update or revise these forward-looking statements whether as a result of new information, future events or otherwise. You are advised, however, to consult any additional disclosure the Company makes on its current reports on Form 6-K to the SEC.

    Herceptin® (trastuzumab) is a registered trademark of Genentech, Inc.

    Taxol® (paclitaxel) is a registered trademark of Bristol-Myers Squibb Company.

        Taxotere® (docetaxel) is a registered trademark of Aventis Pharma S.A


    Arizona Biotech - Small Business Administration - SBA ruling hurts future of biotech companies

    SBA ruling hurts future of biotech companies | ?

    Opinion - Arizona Biotech - Small Business Administration -
    Guest Opinion: Jon McGarity

    SBA ruling hurts future of biotech companies

    Tucson, Arizona | Published: 03.31.2006

    In his 2006 State of the Union address, President Bush declared: "With more research in both the public and private sectors, we will improve our quality of life and ensure America will lead the world in opportunity and innovation for decades to come."

    Unfortunately, the Small Business Administration in Washington, D.C., is not heeding those wise words. In fact, the SBA has imposed a regulatory ruling that is negatively impacting the future of our small biotech and biomedical research companies.

    The SBA decision jeopardizes the development of critical breakthroughs and possible cures for America's patients and their families by cutting off a crucial avenue for our hometown labs to secure much-needed funding from the National Institutes of Health and other federal agencies.

    The SBA decision disqualifies many of our small companies — those firms receiving more than 51 percent of their financial backing from venture capital or other outside interests — from the Small Business Innovation Research grant program.

    It's clear the SBA simply doesn't understand how small biotech and biomedical firms must rely on outside funding to stay competitive while working to get their ideas off the ground and into the marketplace.